Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25082599 | 0.86 | MAOB (0.53) | MAOBCYP19A1HDAC1SIGMAR1HTR1A | |
| SCHEMBL25082372 | 0.86 | MAOB (0.53) | MAOBCYP19A1HDAC1SIGMAR1HTR1A | |
| SCHEMBL13378964 | 0.84 | MAOB (0.60) | MAOBCYP19A1HDAC1SIGMAR1HTR1A | |
| SCHEMBL4040703 | 0.82 | MAOB (0.66) | MAOBCYP19A1HDAC1SIGMAR1HTR1A | |
| SCHEMBL5859931 | 0.82 | MAOB (0.41) | MAOBCYP19A1POLBGAAALDH1A1 | |
| SCHEMBL21979154 | 0.81 | PPARG (0.49) | POLBGAAALDH1A1NPSR1NPC1 | |
| SCHEMBL5858965 | 0.78 | MAOB (0.41) | MAOBCYP19A1POLBGAAALDH1A1 | |
| SCHEMBL11739702 | 0.77 | MAOB (0.52) | MAOBCYP19A1HDAC1SIGMAR1HTR1A | |
| SCHEMBL12164223 | 0.77 | MAOB (0.67) | MAOBCYP19A1HDAC1SIGMAR1HTR1A | |
| SCHEMBL1059845 | 0.77 | MAOB (0.66) | MAOBCYP19A1HDAC1SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109222-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-19 | — | — | US | disclosed |
| US-6867224-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | MAOB 3174/4885CYP19A1 509/4885HDAC1 251/4885 |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | MAOB 3174/4885CYP19A1 509/4885HDAC1 251/4885 |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | MAOB 3174/4885CYP19A1 509/4885HDAC1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.